ALOX15 Inhibitor Patent Application for Respiratory Disorder Treatment

The USPTO published patent application US20260097102A1 covering ALOX15 inhibitors for respiratory disorder treatment. The application discloses methods of treating patients with respiratory disorders using ALOX15 inhibitors, methods for identifying subjects at increased risk of developing respiratory disorders, and methods for detecting human ALOX15 variant nucleic acid molecules and polypeptides.

For pharmaceutical and biotechnology companies, this patent application represents potential future IP competition in the respiratory disorder therapeutic space. Companies developing treatments targeting lipoxygenase pathways should monitor the prosecution of this application to assess freedom-to-operate implications and potential licensing opportunities.